RPS11 and RPS20 have been proposed as prognostic markers in glioblastoma [16] and the down-regulation of RPL10 correlates with altered treatment response to dimethylaminoparthenolide (DMAPT) in pancreatic cancer [22]. Here, RPS20 is linked to pancreatic neoplasm.